Becton, Dickinson and Company (BDX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 16 | 19 | 19 | 19 | 20 | 22 | 21 | 19 |
| Operating profit | $bn | 3 | 2 | ||||||
| Net profit | $bn | 1 | 2 | 2 | 1 | 2 | 2 | 1 | 4 |
| EPS reported | $ | 5.83 | 3.32 | ||||||
| Operating cashflow per share | $ | 11.97 | 12.13 | ||||||
| Capex per share | $ | 2.65 | 2.65 | ||||||
| FCF per share | $ | 9.32 | 9.48 | ||||||
| Free cash flow | $bn | 3 | 3 | ||||||
| Net debt | $bn | 18 | 15 | ||||||
| Book value equity | $bn | 25 | 24 | ||||||
| Book value per share | $ | 88.43 | 88.73 | ||||||
| Number of shares | m | 287.12 | 275.16 | ||||||
| DPS (TTM paid) | $ | 3.50 | 3.98 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 32.10 | 68.96 | ||||||
| P/B LTM | x | 1.66 | 1.73 | ||||||
| P/S LTM | x | 1.93 | 2.02 | ||||||
| P/FCF LTM | x | 15.80 | 16.18 | ||||||
| EV/EBITDA LTM | x | 12.21 | 15.53 | ||||||
| EV/Sales LTM | x | 2.77 | 3.22 | ||||||
| Earnings Yield LTM | % | +3.12% | +1.45% | ||||||
| FCF Yield | % | +6.33% | +6.18% | ||||||
| Quality | |||||||||
| ROE | % | +6.61% | +3.79% | ||||||
| ROIC | % | +4.73% | +3.72% | ||||||
| Operating margin | % | +11.80% | +9.83% | ||||||
| Gross margin | % | +45.44% | +46.12% | ||||||
| FCF/Sales | % | +12.23% | +12.51% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -0.51% | -43.34% | ||||||
| Sales Growth YoY | % | +8.23% | +3.28% | ||||||
| Net Income Growth YoY | % | -1.58% | -44.81% | ||||||
| FCF Growth | % | -13.09% | -15.17% | ||||||
| Operating Profit Growth | % | +7.55% | -14.56% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +2.84% | +2.03% | ||||||
| Dividend Growth | % | +7.32% | +21.89% | ||||||
| Payout Ratio | % | +71.45% | +188.09% | ||||||
| FCF/Debt | x | 0.14 | 0.16 | ||||||
| Net Debt/EBITDA | x | 3.70 | 4.13 | ||||||
| EBIT/Net interest | x | 4.21 | 3.77 | ||||||
| Net debt/market cap | % | +45.48% | +33.02% | ||||||
| Net debt/Equity | x | 0.72 | 0.62 | ||||||
| Gross debt/equity | x | 0.76 | 0.69 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Becton, Dickinson and Company (BDX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free